SillaJen's BAL0891 confirms anticancer effect at European Society for Medical Oncology; response rate of 21.4% in combination group
Predicted impact: Low
Conference data on BAL0891 repeats trial results already reported in the last 14 days.
SillaJen신라젠
215600 · KOSDAQ · ₩215600 · 신라젠
₩2,120▼ ₩10 (0.47%)End-of-day · Oct 28, 2026 · End-of-day prices.
[BioS] SillaJen Presents Interim Results of Phase 1 Solid Tumor Trial of TTK/PLK1 at ESMO
Predicted impact: Low
Interim early-stage trial data presented at a conference; preclinical-stage news is vague.
SillaJen unveils interim results of BAL0891 anticancer drug trial at European Society for Medical Oncology
Predicted impact: Low
SillaJen Unveils Clinical Results for Anticancer Drug BAL0891 at ESMO, "Signs of Efficacy Observed"
Predicted impact: Medium
Clinical efficacy signals for a drug candidate at a major oncology congress; small company.
[ESMO 2026] Lee Su-jin, Executive Director at SillaJen: “BAL0891 maintains complete remission for 7 months”
Predicted impact: Medium
Conference clinical data for BAL0891: complete remission kept 7 months; small-revenue biotech, so data can matter.
Also known as: SillaJen / 신라젠 / 215600 / KRX:215600
Source: KRX statistical information